Antibe Therapeutics Inc (CVE:ATE) Director Daniel Marcel Legault bought 35,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average price of C$0.34 per share, for a total transaction of C$11,900.00. Following the completion of the acquisition, the director now owns 265,000 shares in the company, valued at approximately C$90,100.

Shares of CVE:ATE traded up C$0.01 during mid-day trading on Wednesday, hitting C$0.34. 23,911 shares of the company traded hands, compared to its average volume of 540,813. The company has a market cap of $82.66 million and a P/E ratio of -6.20. The company has a debt-to-equity ratio of 35.82, a quick ratio of 2.10 and a current ratio of 3.77. Antibe Therapeutics Inc has a 52-week low of C$0.24 and a 52-week high of C$0.46.

Antibe Therapeutics (CVE:ATE) last announced its earnings results on Friday, February 15th. The company reported C($0.01) EPS for the quarter, meeting the consensus estimate of C($0.01). The company had revenue of C$2.50 million for the quarter, compared to analysts’ expectations of C$2.20 million. Analysts predict that Antibe Therapeutics Inc will post -0.0299999982352942 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/antibe-therapeutics-inc-ate-director-acquires-c11900-00-in-stock/3011068.html.

Antibe Therapeutics Company Profile

Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.

Featured Article: Calculating net profit and net profit margin ratio

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.